FDA對Nexalin Gen-3 Halo Clarity™頭戴設備計劃中的焦慮症和失眠

快訊 · 06/03 20:30

FDA Provides Feedback and Reaches Consensus on Nexalin’s Design for Planned Anxiety and Insomnia Clinical Studies of Its Gen-3 Halo Clarity™ Headset Device

FDA對Nexalin Gen-3 Halo Clarity™頭戴設備計劃中的焦慮症和失眠症臨床研究的設計提供反饋並達成共識。